221 completed, 88 recruiting, 67 terminated, 43 unknown. 503 Phase 1, 176 Phase 2.
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment Revumenib - Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia | Phase 1 | Not yet recruiting | Syndax Pharmaceuticals | 18 | 2026-11-01 | 2026-11-06 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies MEN2312 - Hematological Malignancy | Phase 1 / Phase 2 | Not yet recruiting | Stemline Therapeutics, Inc. | 115 | 2026-10-30 | 2026-10-14 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-10-28 | 2026-11-02 |
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Arizona | 180 | 2026-10-26 | 2026-10-29 |
| CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 70 | 2026-10-03 | 2026-08-28 |
| CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults CARCIK CD123/33 infusion - AML (Acute Myeloid Leukemia), BPDCN | Phase 1 / Phase 2 | Recruiting | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 18 | 2026-10-01 | 2026-10-16 |
| Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression ORM-1153 - CD123+ Acute Myeloid Leukemia | Phase 1 | Recruiting | Orum Therapeutics USA, Inc. | 42 | 2026-09-23 | 2026-11-02 |
| Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation REGN17235 - Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 52 | 2026-09-17 | 2026-10-27 |
| A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies CD70-targeted chimeric antigen receptor allogeneic T-cell injection (CHT101) - Hematological Malignancies | Phase 1 | Not yet recruiting | Nanjing Miracle Biotechnology Co., Ltd. | 30 | 2026-09-01 | 2026-09-09 |
| A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies CHT101 - Hematological Malignancies | Phase 1 | Not yet recruiting | Nanjing Miracle Biotechnology Co., Ltd. | 30 | 2026-09-01 | 2026-09-09 |
| A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms KK2430 - Hematologic Neoplasms | Phase 1 / Phase 2 | Recruiting | Kyowa Kirin Co., Ltd. | 72 | 2026-08-01 | 2026-08-07 |
| CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation CD45RA-depleted DLI - Hematologic Malignancy, Haplo-identical HCT | Phase 1 | Not yet recruiting | Ruijin Hospital | 30 | 2026-07-01 | 2026-06-29 |
| A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Autologous nano CD5-CAR T Cells - T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2026-06-30 | 2026-07-01 |
| Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. Allogeneic TCR-enhanced Vδ2 T cell Injection, Cyclophosphamide injection, Fludarabine Injection - Hematologic Malignancy, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 24 | 2026-06-05 | 2026-06-08 |
| CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy, Haplo-identical HCT | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 30 | 2026-06-01 | 2026-06-23 |
| CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors Dose Level -1, Dose Level 1 (starting dose level), Dose Level 2 - Lymphoma, Myeloma | Phase 1 | Withdrawn | Baylor College of Medicine | 2026-06-01 | 2026-09-16 | |
| Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders ZE74-0282 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Recruiting | Eilean Therapeutics | 60 | 2026-06-01 | 2026-11-12 |
| Therapeutic RSK1 Targeting in Myeloid Malignancies PMD-026 - Myeloid Malignancy | Phase 1 | Recruiting | Washington University School of Medicine | 30 | 2026-05-20 | 2026-10-21 |
| A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies JNJ-95804306, AML SoC, CLL/SLL SoC - Hematologic Neoplasms | Phase 1 | Recruiting | Janssen Research & Development, LLC | 320 | 2026-05-13 | 2026-11-03 |
Showing 20 of 503. Sign in to see all of them.
Leukemia, Myeloid, Acute (137) · Myelodysplastic Syndromes (95) · Leukemia (89) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (89) · Leukemia, Lymphocytic, Chronic, B-Cell (80) · Multiple Myeloma (78) · Lymphoma (76) · Primary Myelofibrosis (75) · Lymphoma, Non-Hodgkin (72) · Polycythemia Vera (71) · Myeloproliferative Disorders (66) · Thrombocythemia, Essential (55) · Hodgkin Disease (54) · Recurrence (53)
Neoplasms by Site (503) · Hemic and Lymphatic Diseases (502) · Hematologic Diseases (492) · Neoplasms (463) · Neoplasms by Histologic Type (261) · Immune System Diseases (220) · Immunoproliferative Disorders (201) · Lymphoproliferative Disorders (197) · Lymphatic Diseases (188) · Pathological Conditions, Signs and Symptoms (177) · Pathologic Processes (176) · Bone Marrow Diseases (164) · Disease Attributes (158) · Leukemia, Myeloid (151) · Leukemia (132)
Cyclophosphamide (45) · fludarabine (37) · fludarabine phosphate (27) · Azacitidine (19) · Tacrolimus (19) · venetoclax (18) · Cytarabine (14) · Mycophenolic Acid (14) · Rituximab (14) · Whole-Body Irradiation (14) · Busulfan (13) · Peripheral Blood Stem Cell Transplantation (13) · Methotrexate (12) · Sirolimus (12) · Melphalan (11)
National Cancer Institute (NCI) (29) · M.D. Anderson Cancer Center (23) · Fred Hutchinson Cancer Center (10) · City of Hope Medical Center (9) · Incyte Corporation (8) · St. Jude Children's Research Hospital (8) · AbbVie (7) · Bellicum Pharmaceuticals (7) · Chinese PLA General Hospital (7) · Acrotech Biopharma Inc. (6) · Dana-Farber Cancer Institute (6) · Novartis Pharmaceuticals (6) · AstraZeneca (5) · Baylor College of Medicine (5) · Celgene (5)
United States (339) · China (69) · France (41) · Italy (36) · Spain (36) · United Kingdom (33) · Canada (30) · Germany (25) · Australia (24) · Netherlands (16) · Belgium (14) · Japan (14) · Poland (11) · Israel (10) · South Korea (7)
Christopher G Kanakry, M.D. (5) · Ronald Hoffman, MD (4) · Joanne Kurtzberg, MD (3) · Mitchell Horwitz, MD (3) · Neal Flomenberg, MD (3) · Wasim Khan, MD (3)
PMID 34515338, PMID 33795208, PMID 39863139, PMID 41485109, PMID 10845900, PMID 12663454, PMID 15570084, PMID 16732175, PMID 18468541, PMID 18703664, PMID 18820709, PMID 18997826, PMID 19088047, PMID 19238148, PMID 19282026, PMID 19345145, PMID 19713456, PMID 20350611, PMID 20650872, PMID 20733120, PMID 20843246, PMID 21393326, PMID 21417678, PMID 21868572, PMID 22009536, PMID 22198152, PMID 22259028, PMID 22410750, PMID 22491731, PMID 22718840, PMID 22754076, PMID 22840315, PMID 22982675, PMID 23190221, PMID 23682558, PMID 23752175, PMID 23756764, PMID 23802653, PMID 23861248, PMID 23993427, PMID 23996087, PMID 24140121, PMID 24295572, PMID 24474568, PMID 24859366, PMID 24911148, PMID 25075128, PMID 25267759, PMID 25317870, PMID 25428504
2023 (5), 2017 (4), 2019 (4), P30CA015704 (4), P30CA033572 (4), 2016 (3), 2025 (3), UM1CA186691 (3), 2015 (2), P01CA018029 (2), P30CA015083 (2), P30CA016672 (2), U01CA062461 (2), U01CA062490 (2), U01CA062491 (2)